Novel therapeutic strategies in the treatment of triple-negative breast cancer-Reference-Cited by-同舟云学术

Novel therapeutic strategies in the treatment of triple-negative breast cancer

Published:2017-06-13 Issue:7 Volume:9 Page:493-511
ISSN:1758-8359
Container-title:Therapeutic Advances in Medical Oncology
language:en
Short-container-title:Ther Adv Med Oncol

Author:

Oualla Karima¹,El-Zawahry Heba M.²,Arun Banu³,Reuben James M.⁴,Woodward Wendy A.⁵,Gamal El-Din Heba⁶,Lim Bora⁷,Mellas Nawfel¹,Ueno Naoto T.⁷,Fouad Tamer M.⁸

Affiliation:

1. Medical Oncology Department, Hassan II University Hospital, Fes, Morocco

2. Department of Medical Oncology, The National Cancer Institute, Cairo University, Cairo, Egypt

3. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

4. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

5. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

6. Department of Surgical Oncology, The National Cancer Institute, Cairo University, Cairo, Egypt

7. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, TX, USA

8. Department of Medical Oncology, The National Cancer Institute, Cairo University, Kasr El-Aini Road, Cairo, 11796, Egypt

Abstract

Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is defined by negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Treating patients with TNBC remains clinically challenging, as patients are not candidates for endocrine or HER2-directed therapy. As a result, chemotherapy with traditional agents such as anthracyclines and taxanes remains the only available option with moderate success. Recent discoveries have revealed that TNBC is a heterogeneous disease at the clinical, histological and molecular levels. The use of biomarkers to identify distinct subsets of TNBC that derive the greatest benefit from presently approved as well as novel therapeutics has become the main focus of current research. The aim of this review is to explore the clinical and biological complexity of TNBC as well as identify novel therapeutic options that target the various molecular subsets of TNBC.

Publisher

SAGE Publications

Subject

Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1758834017711380

Reference130 articles.

1. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

2. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

3. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

4. Comprehensive molecular portraits of human breast tumours

5. PD-L1 Expression in Triple-Negative Breast Cancer

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel immunotherapies for breast cancer: Focus on 2023 findings;International Immunopharmacology;2024-02

2. Ferroptosis induction via targeting metabolic alterations in triple-negative breast cancer;Biomedicine & Pharmacotherapy;2023-12

3. NAA20 recruits Rin2 and promotes triple-negative breast cancer progression by regulating Rab5A-mediated activation of EGFR signaling;Cellular Signalling;2023-12

4. Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer;Expert Review of Anticancer Therapy;2023-10-03

5. MiR-138-5p improves the chemosensitivity of MDA-MB-231 breast cancer cell line to paclitaxel;Molecular Biology Reports;2023-08-24